Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Simon E. Koele"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 3, Pp 374-385 (2024)
Abstract Adequate power to identify an exposure‐response relationship in a phase IIa clinical trial for pulmonary tuberculosis (TB) is important for dose selection and design of follow‐up studies. Currently, it is not known what response marker p
Externí odkaz:
https://doaj.org/article/788c8eff5be04e00aea81966e1e0d099
Autor:
Simon E. Koele, Patrick P.J. Phillips, Caryn M. Upton, Jakko van Ingen, Ulrika S.H. Simonsson, Andreas H. Diacon, Rob E. Aarnoutse, Elin M. Svensson
Publikováno v:
International Journal of Antimicrobial Agents, 61
International Journal of Antimicrobial Agents, 61, 5
International Journal of Antimicrobial Agents, 61, 5
Contains fulltext : 292507.pdf (Publisher’s version ) (Open Access) A milestone in the development of novel antituberculosis drugs is the demonstration of early bactericidal activity (EBA) in a phase IIa clinical trial. The significant variability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40ac98456de364e058cdbfe76f52d26f
https://doi.org/10.1016/j.ijantimicag.2023.106775
https://doi.org/10.1016/j.ijantimicag.2023.106775
Autor:
Simon E. Koele, Stijn W. van Beek, Anthonie J. van der Wekken, Berber Piet, Michel M. van den Heuvel, Rob ter Heine
Publikováno v:
British Journal of Clinical Pharmacology, 88, 8, pp. 3920-3921
British Journal of Clinical Pharmacology, 88(8), 3920-3921. Wiley
British Journal of Clinical Pharmacology, 88, 3920-3921
British Journal of Clinical Pharmacology, 88(8), 3920-3921. Wiley
British Journal of Clinical Pharmacology, 88, 3920-3921
Contains fulltext : 288320.pdf (Publisher’s version ) (Closed access)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::654aed12f6f7ac87f8170db6d0429ecc
https://doi.org/10.1111/bcp.15321
https://doi.org/10.1111/bcp.15321
Publikováno v:
Antimicrobial Agents and Chemotherapy, 66
Antimicrob Agents Chemother
Antimicrobial Agents and Chemotherapy, 66, 3
Antimicrob Agents Chemother
Antimicrobial Agents and Chemotherapy, 66, 3
Contains fulltext : 249109.pdf (Publisher’s version ) (Open Access) Interruption of treatment is common in drug-resistant tuberculosis patients. Bedaquiline has a long terminal half-life; therefore, restarting after an interruption without a loadin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::088962575427891f1842326906cffa06
http://hdl.handle.net/2066/249109
http://hdl.handle.net/2066/249109
Autor:
Roger J. M. Brüggemann, Eric P H van Dongen, Rob ter Heine, David M. Burger, René M J Wiezer, Roeland E Wasmann, Simon E. Koele, Catherijne A. J. Knibbe, Cornelis Smit
Publikováno v:
Journal of Antimicrobial Chemotherapy, 74, 978-985
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, 74(4), 978-985
Journal of Antimicrobial Chemotherapy, 74, 4, pp. 978-985
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, 74(4), 978-985
Journal of Antimicrobial Chemotherapy, 74, 4, pp. 978-985
Contains fulltext : 202593.pdf (Publisher’s version ) (Closed access) OBJECTIVES: The rising pandemic of obesity means an increasing number of obese patients who require antimicrobial therapy for serious infections. Micafungin is an echinocandin dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90c266ba856bf4023697c0e13aed680e
https://doi.org/10.1093/jac/dky554
https://doi.org/10.1093/jac/dky554